ID: ALA4574644

Max Phase: Preclinical

Molecular Formula: C23H19F3N4O

Molecular Weight: 424.43

Molecule Type: Unknown

Associated Items:

Representations

Canonical SMILES:  FC(F)(F)c1ccc2[nH]c(-c3ccc(-c4ccc(N5CCOCC5)nc4)cc3)nc2c1

Standard InChI:  InChI=1S/C23H19F3N4O/c24-23(25,26)18-6-7-19-20(13-18)29-22(28-19)16-3-1-15(2-4-16)17-5-8-21(27-14-17)30-9-11-31-12-10-30/h1-8,13-14H,9-12H2,(H,28,29)

Standard InChI Key:  YLWOKVBXEDDDHU-UHFFFAOYSA-N

Associated Targets(Human)

Diacylglycerol O-acyltransferase 1 1719 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Acyl coenzyme A:cholesterol acyltransferase 1 857 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

HERG 29587 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: UnknownTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 424.43Molecular Weight (Monoisotopic): 424.1511AlogP: 5.15#Rotatable Bonds: 3
Polar Surface Area: 54.04Molecular Species: NEUTRALHBA: 4HBD: 1
#RO5 Violations: 1HBA (Lipinski): 5HBD (Lipinski): 1#RO5 Violations (Lipinski): 1
CX Acidic pKa: 11.41CX Basic pKa: 5.94CX LogP: 5.08CX LogD: 5.06
Aromatic Rings: 4Heavy Atoms: 31QED Weighted: 0.49Np Likeness Score: -1.82

References

1. Yu Y, Wu Z, Shi ZC, He S, Lai Z, Cernak TA, Vachal P, Liu M, Liu J, Hong Q, Jian T, Guiadeen D, Krikorian A, Sperbeck DM, Verras A, Sonatore LM, Murphy BA, Wiltsie J, Chung CC, Gorski JN, Liu J, Xiao J, Wolff M, Tong SX, Madeira M, Karanam BV, Shen DM, Balkovec JM, De Vita RJ, Pinto S, Nargund RP..  (2019)  Accelerating the discovery of DGAT1 inhibitors through the application of parallel medicinal chemistry (PMC).,  29  (11): [PMID:30952592] [10.1016/j.bmcl.2019.03.039]

Source